Association of dengue virus-specific polyfunctional T-cell responses with clinical disease severity in acute dengue infection.
clinical disease severity
cytokines
dengue
polyfunctional T cells
Journal
Immunity, inflammation and disease
ISSN: 2050-4527
Titre abrégé: Immun Inflamm Dis
Pays: England
ID NLM: 101635460
Informations de publication
Date de publication:
12 2019
12 2019
Historique:
received:
26
03
2019
revised:
31
07
2019
accepted:
27
08
2019
pubmed:
1
10
2019
medline:
27
3
2020
entrez:
1
10
2019
Statut:
ppublish
Résumé
Although the role of dengue virus (DENV)-specific T cells in the pathogenesis of acute dengue infection is emerging, the functionality of virus-specific T cells associated with milder clinical disease has not been well studied. We sought to investigate how the functionality of DENV-NS3 and DENV-NS5 protein-specific T cells differ in patients with dengue fever (DF) and dengue hemorrhagic fever (DHF). Using intracellular cytokine assays, we assessed the production of interferon γ (IFNγ), tumor necrosis factor-α (TNF-α), macrophage inflammatory protein-1β (MIP-1β), and CD107a expression in adult patients with acute DF (n = 21) and DHF (n = 22). Quadruple cytokine-producing, polyfunctional DENV-NS3- and DENV-NS5-specific T cells were more frequent in those with DF when compared to those with DHF. While DENV-NS3- and DENV-NS5-specific T cells in patients with DF expressed IFNγ > TNF-α > MIP-β > CD107a, T cells of those with DHF predominantly expressed CD107a > MIP-1β > IFNγ > TNF-α. Overall production of IFNγ or TNF-α by DENV-NS3- and DENV-NS5-specific T cells was significantly higher in patients with DF. The majority of NS3-specific T cells in patients with DF (78.6%) and DHF (68.9%) were single-cytokine producers; 76.6% of DENV-NS5-specific T cells in those with DF and 77.1% of those with DHF, produced only a single cytokine. However, no significant association was found with polyfunctional T-cell responses and the degree of viraemia. Our results suggest that the functional phenotype of DENV-specific T cells are likely to associate with clinical disease severity.
Identifiants
pubmed: 31568656
doi: 10.1002/iid3.271
pmc: PMC6842812
doi:
Substances chimiques
Cytokines
0
NS3 protein, flavivirus
0
NS5 protein, dengue virus
0
Viral Nonstructural Proteins
0
Serine Endopeptidases
EC 3.4.21.-
RNA Helicases
EC 3.6.4.13
Types de publication
Clinical Trial
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
276-285Subventions
Organisme : Department of Health
Pays : United Kingdom
Organisme : Medical Research Council
ID : MC_U137881017
Pays : United Kingdom
Organisme : Medical Research Council
ID : G116/150
Pays : United Kingdom
Organisme : Wellcome Trust
ID : 209222/Z/17/Z
Pays : United Kingdom
Organisme : Medical Research Council
ID : G0701693
Pays : United Kingdom
Organisme : Medical Research Council
ID : MC_UU_12010/5
Pays : United Kingdom
Organisme : Medical Research Council
ID : MC_PC_14131
Pays : United Kingdom
Organisme : Medical Research Council
ID : MC_PC_14103
Pays : United Kingdom
Organisme : Medical Research Council
ID : MC_UU_00008/5
Pays : United Kingdom
Informations de copyright
© 2019 The Authors. Immunity, Inflammation and Disease published by John Wiley & Sons Ltd.
Références
PLoS One. 2012;7(7):e37535
pubmed: 22829867
Immun Inflamm Dis. 2019 Dec;7(4):276-285
pubmed: 31568656
Nature. 2013 Apr 25;496(7446):504-7
pubmed: 23563266
J Virol. 2016 Nov 28;90(24):11259-11278
pubmed: 27707928
J Infect Dis. 2011 May 1;203(9):1282-91
pubmed: 21335561
PLoS Pathog. 2013;9(7):e1003504
pubmed: 23874205
Am J Respir Crit Care Med. 2016 Jan 1;193(1):78-85
pubmed: 26372850
BMC Infect Dis. 2016 Jul 08;16:319
pubmed: 27391896
Front Immunol. 2018 Feb 16;9:276
pubmed: 29503649
PLoS Negl Trop Dis. 2018 Oct 1;12(10):e0006540
pubmed: 30273352
J Virol. 2005 May;79(9):5665-75
pubmed: 15827181
Methods Mol Biol. 2019;1911:349-361
pubmed: 30593638
PLoS Negl Trop Dis. 2013 Sep 05;7(9):e2409
pubmed: 24040431
Vaccine. 2019 Aug 14;37(35):4848-4849
pubmed: 30424888
J Virol. 2015 Jan;89(1):120-8
pubmed: 25320311
Exp Mol Med. 2017 Sep 29;49(9):e382
pubmed: 28960213
Clin Vaccine Immunol. 2007 Aug;14(8):969-77
pubmed: 17567768
J Clin Invest. 2008 Mar;118(3):1143-53
pubmed: 18246203
J Infect Dis. 2015 Nov 15;212(10):1618-28
pubmed: 25943203
Immunology. 2005 Jun;115(2):239-45
pubmed: 15885130
J Exp Med. 2004 Apr 5;199(7):925-36
pubmed: 15051762
Nat Rev Immunol. 2008 Apr;8(4):247-58
pubmed: 18323851
Hum Vaccin Immunother. 2012 Sep;8(9):1259-71
pubmed: 22894958
PLoS Negl Trop Dis. 2015 Apr 13;9(4):e0003673
pubmed: 25875020
Cell Immunol. 2009;254(2):149-54
pubmed: 18835598
Proc Natl Acad Sci U S A. 2018 Aug 7;115(32):E7578-E7586
pubmed: 30038008
J Infect Dis. 2015 Dec 1;212(11):1743-51
pubmed: 25980035
Hum Vaccin Immunother. 2018;14(9):2158-2162
pubmed: 29482433
J Infect Dis. 2007 Jun 15;195(12):1799-807
pubmed: 17492596
J Virol. 2002 Feb;76(3):1071-6
pubmed: 11773383
Clin Diagn Lab Immunol. 1998 Jan;5(1):7-10
pubmed: 9455871
PLoS Negl Trop Dis. 2013 Jul 11;7(7):e2311
pubmed: 23875046
PLoS One. 2012;7(11):e50387
pubmed: 23209731
Blood. 2006 Jun 15;107(12):4781-9
pubmed: 16467198
Nat Med. 2003 Jul;9(7):921-7
pubmed: 12808447
FEMS Immunol Med Microbiol. 2003 Jan 21;35(1):33-42
pubmed: 12589955
J Immunol. 2006 Mar 15;176(6):3821-9
pubmed: 16517753
Proc Natl Acad Sci U S A. 2015 Aug 4;112(31):E4256-63
pubmed: 26195744
Sci Transl Med. 2015 Mar 11;7(278):278ra35
pubmed: 25761891
Proc Natl Acad Sci U S A. 2013 May 28;110(22):E2046-53
pubmed: 23580623
Immunol Rev. 2008 Oct;225:300-13
pubmed: 18837790
Methods Mol Biol. 2018;1808:173-179
pubmed: 29956183
PLoS One. 2007 Dec 05;2(12):e1192
pubmed: 18060049
J Virol. 2009 Jun;83(11):5514-24
pubmed: 19297503